“Editas Medicine announced on February 16 the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield is currently the Chairperson of the Board of Trustees of the Joslin Diabetes Center and serves as Lead Independent Director on the Board of Directors of Insulet Corporation. We believe Dr. Hopfield will bring significant commercial and operational experience to the Editas board.”,” the firm’s analyst commented.
Several other equities analysts have also recently weighed in on EDIT. ValuEngine cut Editas Medicine from a hold rating to a sell rating in a research report on Wednesday, October 25th. Cowen reissued a buy rating on shares of Editas Medicine in a research report on Tuesday, November 7th. Zacks Investment Research raised Editas Medicine from a hold rating to a buy rating and set a $25.00 price objective for the company in a research report on Friday, November 10th. BidaskClub cut Editas Medicine from a buy rating to a hold rating in a research report on Thursday, December 7th. Finally, SunTrust Banks raised Editas Medicine from a hold rating to a buy rating and boosted their price objective for the stock from $17.00 to $45.00 in a research report on Tuesday, January 23rd. Three analysts have rated the stock with a sell rating, four have assigned a hold rating, four have given a buy rating and two have issued a strong buy rating to the company’s stock. Editas Medicine has a consensus rating of Hold and an average target price of $30.02.
In other Editas Medicine news, CFO Andrew A. F. Hack sold 18,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $34.21, for a total value of $615,780.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew A. F. Hack sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $24.31, for a total value of $121,550.00. Following the completion of the transaction, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at approximately $121,550. The disclosure for this sale can be found here. In the last ninety days, insiders sold 92,648 shares of company stock valued at $3,052,489. Insiders own 19.40% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Slow Capital Inc. acquired a new position in Editas Medicine in the 4th quarter valued at approximately $391,000. MetLife Investment Advisors LLC acquired a new position in Editas Medicine in the 4th quarter valued at approximately $509,000. Glenmede Trust Co. NA acquired a new position in Editas Medicine in the 4th quarter valued at approximately $153,000. Financial Advocates Investment Management acquired a new position in Editas Medicine in the 4th quarter valued at approximately $319,000. Finally, Millennium Management LLC raised its holdings in Editas Medicine by 13.2% in the 4th quarter. Millennium Management LLC now owns 422,757 shares of the company’s stock valued at $12,991,000 after acquiring an additional 49,336 shares in the last quarter. 69.66% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Editas Medicine (EDIT) Given Hold Rating at Cann” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2018/02/20/editas-medicine-edit-given-hold-rating-at-cann.html.
About Editas Medicine
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.